University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Felix Y. Feng, MD

Felix Y. Feng, MD

Associate Professor of Radiation Oncology, Depts. of Urology and Medicine; Vice Chair for Faculty Development and Director of Translational Research, Department of Radiation Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer | Cancer Genetics

Research Summary

I am a physician-scientist focused on clinical and translational research aimed at improving outcomes for patients with prostate cancer. My research interests include 1) the discovery of prognostic/predictive biomarkers in prostate cancer and 2) the development of rational approaches of targeted treatment for therapy-resistant disease. My laboratory focuses on sequencing and microarray-based approaches to identify molecular determinants of response from samples from prostate cancer patients treated on clinical trials. In addition, I am co-principal investigator of one of the first biomarker-driven clinical trials for patients with metastatic prostate cancer (NCI 9012; NCT01576172) and oversee a clinic focused on prostate cancer patients.


Stanford University, B.S., 06/1998, Biological Studies
Washington University School of Medicine, M.D., 06/2002, Medicine

Professional Experience

  • 2002-2003
    Intern, Dept of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor MI
  • 2003-2005
    Resident, Dept of Radiology, University of Michigan Medical Center, Ann Arbor, MI
  • 2005-2006
    Post-Doctoral Research Fellow, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2006-2010
    Resident, Dept of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
  • 2009-2010
    Chief Resident, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2016
    Assistant Professor, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2010-2012
    Assistant Professor, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2010-present
    Leader, the Genitourinary Cancer Translational Research Program for the NRG/RTOG Cooperative Group
  • 2011
    Acting Chief, Radiation Oncology, Dept of Radiation Oncology, Ann Arbor Veteran's Health System, Ann Arbor, MI
  • 2013-2016
    Director, Division of Translational Genomics, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2015-2016
    Associate Chair for Laboratory Research, Dept of Radiation Oncology, Univ of Michigan Medical Center, Ann Arbor, MI
  • 2016-present
    Associate Professor of Radiation Oncology, Urology, and Medicine
  • 2016-present
    Vice Chair for Faculty Development and Translational Research, Dept of Radiation Oncology, University of California at San Francisco, CA

Honors & Awards

  • 1997
    Barry M. Goldwater Fellowship for Excellence in Mathematics, Science, and Engineering
  • 1998-2002
    Dr. Philip Majerus Distinguished Alumni Scholarship
  • 2002
    Dr. Richard S. Brookings Medical School Prize
  • 2008
    American Society of Therapeutic Radiology and Oncology Resident Clinical Research Award
  • 2010
    Radiological Society of North America Roentgen Resident/Fellow Research Award
  • 2012
    American Society of Radiation Oncology Basic Science Award
  • 2014
    Radiobiology Teacher of the Year, Dept of Radiation Oncology, University of Michigan
  • 2016
    American Society of Radiation Oncology Clinical Science Award

Selected Publications

  1. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg M, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 May 18.
    View on PubMed
  2. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11.
    View on PubMed
  3. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Apr 27.
    View on PubMed
  4. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson A, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubedi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res. 2016 Dec 23.
    View on PubMed
  5. Dess RT, Jackson WC, Suy S, Soni PD, Lee JY, Abugharib AE, Zumsteg ZS, Feng FY, Hamstra DA, Collins SP, Spratt DE. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer. Cancer. 2016 Dec 21.
    View on PubMed
  6. Tan M, Xu J, Siddiqui J, Feng F, Sun Y. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer. 2016 Dec 12; 15(1):81.
    View on PubMed
  7. Wahl DR, Dresser J, Wilder-Romans K, Parsels JD, Zhao SG, Davis M, Zhao L, Kachman M, Wernisch S, Burant CF, Morgan MA, Feng FY, Speers C, Lyssiotis CA, Lawrence TS. Glioblastoma therapy can be augmented by targeting IDH1-mediated NADPH biosynthesis. Cancer Res. 2016 Dec 06.
    View on PubMed
  8. Thangavel C, Boopathi E, Liu Y, Haber A, Ertel A, Bhardwaj A, Addya S, Williams N, Ciment S, Cotzia P, Dean JL, Snook AE, McNair C, Price MA, Hernandez JR, Zhao SG, Birbe R, McCarthy JB, Turely EA, Pienta KJ, Feng FY, Dicker AP, Knudsen KE, Den RB. RB loss promotes prostate cancer metastasis. Cancer Res. 2016 Dec 06.
    View on PubMed
  9. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. Osteoporos Int. 2016 Nov 14.
    View on PubMed
  10. Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2017 Jan; 109(1).
    View on PubMed
  11. Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, Prensner JR, Poliakov A, Singhal U, Xiao L, Kregel S, Siebenaler RF, Zhao SG, Uhl M, Gawronski A, Hayes DF, Pierce LJ, Cao X, Collins C, Backofen R, Sahinalp CS, Rae JM, Chinnaiyan AM, Feng FY. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 2016 Sep 26; 7:12791.
    View on PubMed
  12. McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 2016 Sep 26.
    View on PubMed
  13. Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY. Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. Semin Radiat Oncol. 2017 Jan; 27(1):11-20.
    View on PubMed
  14. Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Zumsteg ZS, Mehra R, Feng FY, Morgan TM, Desai N, Spratt DE. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J Urol. 2016 Sep 07.
    View on PubMed
  15. Guo H, Ahmed M, Zhang F, Yao CQ, Li S, Liang Y, Hua J, Soares F, Sun Y, Langstein J, Li Y, Poon C, Bailey SD, Desai K, Fei T, Li Q, Sendorek DH, Fraser M, Prensner JR, Pugh TJ, Pomerantz M, Bristow RG, Lupien M, Feng FY, Boutros PC, Freedman ML, Walsh MJ, He HH. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 Oct; 48(10):1142-50.
    View on PubMed
  16. Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys. 2016 Nov 15; 96(4):770-777.
    View on PubMed
  17. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016 Aug 1; 126(8):2775-82.
    View on PubMed
  18. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in Genomic Sequencing. JAMA Oncol. 2016 Aug 1; 2(8):1070-4.
    View on PubMed
  19. Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cieslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. Neoplasia. 2016 Aug; 18(8):489-99.
    View on PubMed
  20. Jackson WC, Schipper MJ, Feng FY. Reply to Yu-Wen Hu's Letter to the Editor re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Eur Urol. 2016 Dec; 70(6):e159.
    View on PubMed

Go to UCSF Profiles, powered by CTSI